Literature DB >> 11865060

Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation.

Joon-Ho Sheen1, Robert B Dickson.   

Abstract

Study of the mechanism(s) of genomic instability induced by the c-myc proto-oncogene has the potential to shed new light on its well-known oncogenic activity. However, an underlying mechanism(s) for this phenotype is largely unknown. In the present study, we investigated the effects of c-Myc overexpression on the DNA damage-induced G(1)/S checkpoint, in order to obtain mechanistic insights into how deregulated c-Myc destabilizes the cellular genome. The DNA damage-induced checkpoints are among the primary safeguard mechanisms for genomic stability, and alterations of cell cycle checkpoints are known to be crucial for certain types of genomic instability, such as gene amplification. The effects of c-Myc overexpression were studied in human mammary epithelial cells (HMEC) as one approach to understanding the c-Myc-induced genomic instability in the context of mammary tumorigenesis. Initially, flow-cytometric analyses were used with two c-Myc-overexpressing, nontransformed immortal lines (184A1N4 and MCF10A) to determine whether c-Myc overexpression leads to alteration of cell cycle arrest following ionizing radiation (IR). Inappropriate entry into S phase was then confirmed with a bromodeoxyuridine incorporation assay measuring de novo DNA synthesis following IR. Direct involvement of c-Myc overexpression in alteration of the G(1)/S checkpoint was then confirmed by utilizing the MycER construct, a regulatable c-Myc. A transient excess of c-Myc activity, provided by the activated MycER, was similarly able to induce the inappropriate de novo DNA synthesis following IR. Significantly, the transient expression of full-length c-Myc in normal mortal HMECs also facilitated entry into S phase and the inappropriate de novo DNA synthesis following IR. Furthermore, irradiated, c-Myc-infected, normal HMECs developed a sub-G(1) population and a >4N population of cells. The c-Myc-induced alteration of the G(1)/S checkpoint was also compared to the effects of expression of MycS (N-terminally truncated c-Myc) and p53DD (a dominant negative p53) in the HMECs. We observed inappropriate hyperphosphorylation of retinoblastoma protein and then the reappearance of cyclin A, following IR, selectively in full-length c-Myc- and p53DD-overexpressing MCF10A cells. Based on these results, we propose that c-Myc attenuates a safeguard mechanism for genomic stability; this property may contribute to c-Myc-induced genomic instability and to the potent oncogenic activity of c-Myc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865060      PMCID: PMC135614          DOI: 10.1128/MCB.22.6.1819-1833.2002

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

Review 1.  Cellular senescence: mitotic clock or culture shock?

Authors:  C J Sherr; R A DePinho
Journal:  Cell       Date:  2000-08-18       Impact factor: 41.582

2.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

Authors:  L R Livingstone; A White; J Sprouse; E Livanos; T Jacks; T D Tlsty
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

Review 3.  Mutator phenotype may be required for multistage carcinogenesis.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

Review 4.  The Myc:Max protein complex and cell growth regulation.

Authors:  E M Blackwood; B Lüscher; L Kretzner; R N Eisenman
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1991

5.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

Authors:  H A Coller; C Grandori; P Tamayo; T Colbert; E S Lander; R N Eisenman; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

6.  A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest.

Authors:  G F Claassen; S R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

7.  Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts.

Authors:  S K Hirst; C Grandori
Journal:  Oncogene       Date:  2000-10-26       Impact factor: 9.867

8.  Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts.

Authors:  D W Felsher; A Zetterberg; J Zhu; T Tlsty; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

9.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

Authors:  Y Yin; M A Tainsky; F Z Bischoff; L C Strong; G M Wahl
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

10.  Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.

Authors:  S J McCormack; Z Weaver; S Deming; G Natarajan; J Torri; M D Johnson; M Liyanage; T Ried; R B Dickson
Journal:  Oncogene       Date:  1998-05-28       Impact factor: 9.867

View more
  24 in total

1.  The role of circadian rhythm in breast cancer.

Authors:  Shujing Li; Xiang Ao; Huijian Wu
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

2.  The involvement of c-Myc in the DNA double-strand break repair via regulating radiation-induced phosphorylation of ATM and DNA-PKcs activity.

Authors:  Fengmei Cui; Rong Fan; Qiu Chen; Yongming He; Man Song; Zengfu Shang; Shimeng Zhang; Wei Zhu; Jianping Cao; Hua Guan; Ping-Kun Zhou
Journal:  Mol Cell Biochem       Date:  2015-06-07       Impact factor: 3.396

3.  MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities.

Authors:  Julia Rohrberg; Daniel Van de Mark; Meelad Amouzgar; Joyce V Lee; Moufida Taileb; Alexandra Corella; Seda Kilinc; Jeremy Williams; Marie-Lena Jokisch; Roman Camarda; Sanjeev Balakrishnan; Rama Shankar; Alicia Zhou; Aaron N Chang; Bin Chen; Hope S Rugo; Sophie Dumont; Andrei Goga
Journal:  Cell Rep       Date:  2020-03-10       Impact factor: 9.423

Review 4.  Genetic and epigenetic features in radiation sensitivity Part I: cell signalling in radiation response.

Authors:  Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02       Impact factor: 9.236

5.  Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response.

Authors:  Joshua R Porter; Brian E Fisher; Laura Baranello; Julia C Liu; Diane M Kambach; Zuqin Nie; Woo Seuk Koh; Ji Luo; Jayne M Stommel; David Levens; Eric Batchelor
Journal:  Mol Cell       Date:  2017-08-31       Impact factor: 17.970

6.  c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.

Authors:  Kirsteen H Maclean; Ulrich B Keller; Carlos Rodriguez-Galindo; Jonas A Nilsson; John L Cleveland
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage.

Authors:  Lina Guerra; Ami Albihn; Susanna Tronnersjö; Qinzi Yan; Riccardo Guidi; Bo Stenerlöw; Torsten Sterzenbach; Christine Josenhans; James G Fox; David B Schauer; Monica Thelestam; Lars-Gunnar Larsson; Marie Henriksson; Teresa Frisan
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

8.  Circadian rhythm and its role in malignancy.

Authors:  Sobia Rana; Saqib Mahmood
Journal:  J Circadian Rhythms       Date:  2010-03-31

9.  c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Krishna Beer Singh; Shivendra V Singh
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

10.  c-myc amplifications in primary breast carcinomas and their local recurrences.

Authors:  S Aulmann; N Adler; J Rom; B Helmchen; P Schirmacher; H P Sinn
Journal:  J Clin Pathol       Date:  2006-02-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.